U.S. Government Hinders Gender Affirmation Surgeries for Minors

The U.S. government has moved to restrict gender-affirming care for minors by blocking federal funding for such treatments. On December 5, 2025, the Department of Health and Human Services (HHS) announced new rules preventing hospitals in Medicaid and Medicare programs from billing for these procedures. The decision has reignited debates over medical care for transgender youth.

The proposed rule, issued under HHS Secretary Robert F. Kennedy Jr., bans gender-affirming medical interventions—including hormone therapy and surgeries—for anyone under 19. The policy was formally announced through a press release and a Federal Register notice on the same day. While the U.S. Food and Drug Administration (FDA) has not altered its own regulations on these treatments, the HHS decision effectively cuts off federal reimbursement.

Critics argue the restrictions prioritise political ideology over medical evidence, potentially harming vulnerable minors. Healthcare advocates warn that denying access to these treatments could worsen mental health outcomes for transgender youth. Supporters, however, claim the rules protect children from irreversible medical decisions. The issue remains deeply divisive in U.S. politics, influencing elections and public discourse. Previous attempts to limit gender-affirming care under the Trump administration faced legal challenges and protests. Opponents have already accused policymakers of overreach, setting the stage for further confrontation.

The new guidelines will prevent federal funding for gender-affirming treatments for minors, regardless of medical necessity. Hospitals participating in Medicaid and Medicare will no longer receive reimbursements for such procedures. The policy’s impact on transgender youth and the broader healthcare system is expected to unfold in the coming months.